Cargando…
Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study
BACKGROUND: Vedolizumab demonstrated different placental pharmacokinetics than other immunoglobulin G1 antibodies, leading to lower drug levels in cord blood in contrast to maternal blood at the time of delivery. The placental transfer of ustekinumab seems to have a pattern similar to anti-tumour ne...
Autores principales: | Mitrova, Katarina, Pipek, Barbora, Bortlik, Martin, Bouchner, Ludek, Brezina, Jan, Douda, Tomas, Drasar, Tomas, Drastich, Pavel, Falt, Premysl, Klvana, Pavel, Leksa, Vaclav, Novotny, Ales, Svoboda, Pavel, Skorpik, Jan, Ulbrych, Jan, Veinfurt, Marek, Zborilova, Blanka, Lukas, Milan, Duricova, Dana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358502/ https://www.ncbi.nlm.nih.gov/pubmed/34394725 http://dx.doi.org/10.1177/17562848211032790 |
Ejemplares similares
-
Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis
por: Keil, Radan, et al.
Publicado: (2016) -
Su1497: EFFECT OF SARS COV-2 VACCINE IN IBD PATIENTS ON BIOLOGIC THERAPY INCLUDING LIVER TRANSPLANT RECIPIENTS.
por: Brezina, Jan, et al.
Publicado: (2022) -
Fecal Microbial Transplantation versus Mesalamine Enema for Treatment of Active Left-Sided Ulcerative Colitis—Results of a Randomized Controlled Trial
por: Březina, Jan, et al.
Publicado: (2021) -
Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017) -
A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)